147 related articles for article (PubMed ID: 19961222)
41. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
[TBL] [Abstract][Full Text] [Related]
42. High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations.
Wannberg J; Kaiser NF; Vrang L; Samuelsson B; Larhed M; Hallberg A
J Comb Chem; 2005; 7(4):611-7. PubMed ID: 16004505
[TBL] [Abstract][Full Text] [Related]
43. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
[TBL] [Abstract][Full Text] [Related]
44. Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors.
Yanada R; Koh Y; Nishimori N; Matsumura A; Obika S; Mitsuya H; Fujii N; Takemoto Y
J Org Chem; 2004 Apr; 69(7):2417-22. PubMed ID: 15049639
[TBL] [Abstract][Full Text] [Related]
45. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
46. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
[TBL] [Abstract][Full Text] [Related]
47. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.
Pyring D; Lindberg J; Rosenquist A ; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Unge T; Classon B; Hallberg A; Samuelsson B
J Med Chem; 2001 Sep; 44(19):3083-91. PubMed ID: 11543677
[TBL] [Abstract][Full Text] [Related]
50. Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization.
Vidu A; Dufau L; Bannwarth L; Soulier JL; Sicsic S; Piarulli U; Reboud-Ravaux M; Ongeri S
ChemMedChem; 2010 Nov; 5(11):1899-906. PubMed ID: 20936621
[TBL] [Abstract][Full Text] [Related]
51. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
[TBL] [Abstract][Full Text] [Related]
52. Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases.
Bonini C; Chiummiento L; De Bonis M; Di Blasio N; Funicello M; Lupattelli P; Pandolfo R; Tramutola F; Berti F
J Med Chem; 2010 Feb; 53(4):1451-7. PubMed ID: 20108932
[TBL] [Abstract][Full Text] [Related]
53. 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Degoey DA; Grampovnik DJ; Flentge CA; Flosi WJ; Chen HJ; Yeung CM; Randolph JT; Klein LL; Dekhtyar T; Colletti L; Marsh KC; Stoll V; Mamo M; Morfitt DC; Nguyen B; Schmidt JM; Swanson SJ; Mo H; Kati WM; Molla A; Kempf DJ
J Med Chem; 2009 Apr; 52(8):2571-86. PubMed ID: 19323562
[TBL] [Abstract][Full Text] [Related]
54. Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.
Alterman M; Andersson HO; Garg N; Ahlsén G; Lövgren S; Classon B; Danielson UH; Kvarnström I; Vrang L; Unge T; Samuelsson B; Hallberg A
J Med Chem; 1999 Sep; 42(19):3835-44. PubMed ID: 10508432
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
Ghosh AK; Jadhav RD; Simpson H; Kovela S; Osswald H; Agniswamy J; Wang YF; Hattori SI; Weber IT; Mitsuya H
Eur J Med Chem; 2018 Dec; 160():171-182. PubMed ID: 30340140
[TBL] [Abstract][Full Text] [Related]
57. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
Kiso Y
Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
[No Abstract] [Full Text] [Related]
59. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
[TBL] [Abstract][Full Text] [Related]
60. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
